Estrella Immunopharma, INC. (ESLAW) — 10-Q Filings

All 10-Q filings from Estrella Immunopharma, INC.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (6)

Estrella Immunopharma's Net Loss Widens 59.6% Amid R&D Surge — Nov 12, 2025 Risk: high
Estrella Immunopharma, Inc. (ESLAW) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching approximately $12.45 mill
Estrella Immunopharma's Net Loss Widens 73% Amid R&D Surge — Aug 12, 2025 Risk: high
Estrella Immunopharma, Inc. (ESLAW) reported a significant increase in net loss for the six months ended June 30, 2025, reaching $7,649,189, up from $4,420,602
Estrella Immunopharma Files Q1 2025 10-Q — May 14, 2025 Risk: low
Estrella Immunopharma, Inc. filed its quarterly report for the period ended March 31, 2025. The company, formerly known as TradeUP Acquisition Corp., is focused
Estrella Immunopharma Files Q3 2024 10-Q — Nov 14, 2024 Risk: low
Estrella Immunopharma, Inc. filed its 10-Q for the quarterly period ended September 30, 2024. The company, formerly known as TradeUP Acquisition Corp. until Feb
Estrella Immunopharma, Inc. Files 10-Q for Period Ended March 31, 2024 — May 15, 2024 Risk: low
Estrella Immunopharma, Inc. (ESLAW) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Estrella Immunopharma, Inc. filed a 10-Q report for the quarte
Estrella Immunopharma, Inc. Files 10-Q for Period Ended December 31, 2023 — Feb 14, 2024 Risk: low
Estrella Immunopharma, Inc. (ESLAW) filed a Quarterly Report (10-Q) with the SEC on February 14, 2024. Estrella Immunopharma, Inc. filed a 10-Q report for the q

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX